Biotricity (BTCY)
(Delayed Data from OTC)
$0.30 USD
+0.10 (50.00%)
Updated Oct 2, 2024 03:56 PM ET
3-Hold of 5 3
F Value B Growth C Momentum C VGM
Income Statements
Fiscal Year end for Biotricity Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | 12 | 10 | 8 | 3 | 1 |
Cost Of Goods | 4 | 4 | 3 | 2 | 1 |
Gross Profit | 8 | 5 | 5 | 2 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 17 | 21 | 23 | 15 | 12 |
Income After Depreciation & Amortization | -9 | -15 | -18 | -13 | -11 |
Non-Operating Income | -2 | -1 | -11 | 2 | 0 |
Interest Expense | 3 | 2 | 0 | 0 | 0 |
Pretax Income | -14 | -19 | -29 | -15 | -11 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -14 | -19 | -29 | -15 | -11 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -14 | -19 | -29 | -15 | -11 |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -7 | -15 | -9 | -11 | -11 |
Depreciation & Amortization (Cash Flow) | 2 | 1 | 9 | 2 | 0 |
Income After Depreciation & Amortization | -9 | -15 | -18 | -13 | -11 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | 8.99 | 8.66 | 7.57 | 6.26 | NA |
Diluted EPS Before Non-Recurring Items | -1.66 | -2.28 | -4.02 | -2.64 | NA |
Diluted Net EPS (GAAP) | -1.66 | -2.26 | -3.99 | -2.63 | -1.89 |
Fiscal Year end for Biotricity Inc falls in the month of March .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 3.20 | 3.18 | 2.97 | 2.89 | 3.02 |
Cost Of Goods | 0.84 | 0.91 | 0.80 | 0.89 | 1.10 |
Gross Profit | 2.36 | 2.27 | 2.17 | 2.00 | 1.92 |
SG&A, R&D, and Dept/Amort Expenses | 3.48 | 5.32 | 3.45 | 4.19 | 4.23 |
Income After SG&A, R&D, and Dept/Amort Expenses | -1.12 | -3.05 | -1.28 | -2.19 | -2.31 |
Non-Operating Income | -1.81 | -0.32 | -0.74 | -0.75 | -0.44 |
Interest Expense | 0.77 | 0.81 | 0.79 | 0.75 | 0.66 |
Pretax Income | -3.69 | -4.18 | -2.81 | -3.69 | -3.41 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -3.69 | -4.18 | -2.81 | -3.69 | -3.41 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -3.69 | -4.18 | -2.81 | -3.69 | -3.41 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 14.17 | 9.37 | 8.98 | 8.80 | 52.52 |
Diluted EPS Before Non-Recurring Items | -0.49 | -0.47 | -0.34 | -0.44 | -0.07 |
Diluted Net EPS (GAAP) | -0.49 | -0.81 | -0.34 | -0.44 | -0.07 |